ABSTRACT

Initially, acute loss of smell (anosmia) and taste (ageusia) was not considered important symptoms for coronavirus disease 2019 (COVID-19). To determine the prevalence of these symptoms and to evaluate their diagnostic significance, we (approximately 150 physicians of the Daegu Medical Association) prospectively collected data of cases of anosmia and ageusia from March 8, 2020, via telephone interview among 3,191 patients in Daegu, Korea. Acute anosmia or ageusia was observed in 15.3% (488/3,191) patients in the early stage of COVID-19 and in 15.7% (367/2,342) patients with asymptomatic-to-mild disease severity. Their prevalence was significantly more common among females and younger individuals (P = 0.01 and P < 0.001, respectively). Most patients with anosmia or ageusia recovered within 3 weeks. The median time to recovery was 7 days for both symptoms. Anosmia and ageusia seem to be part of important symptoms and clues for the diagnosis of COVID-19, particularly in the early stage of the disease.

Keywords: Loss of Smell; Anosmia; Loss of Taste; Ageusia; COVID-19
Acute Loss of Smell or Taste in COVID-19 Patients

taste (ageusia). Acute smell and taste disorders are related to a wide range of respiratory viral infections.\textsuperscript{2,3}

COVID-19 is characterized by a variety of clinical manifestations.\textsuperscript{4} In a typical case, a high fever appears after dry cough; in some cases, viral pneumonia develops and progresses, resulting in shortness of breath.\textsuperscript{4,5} Common symptoms among patients with COVID-19 include fever, dry cough, shortness of breath (dyspnea), muscle ache (myalgia), confusion, headache, sore throat, rhinorrhea, chest pain, diarrhea, nausea/vomiting, conjunctival congestion, nasal congestion, sputum production, fatigue (malaise), hemoptyisis, and chills.\textsuperscript{4,6-9} A literature review revealed a few published articles on the importance of anosmia or ageusia as symptoms of COVID-19.\textsuperscript{10-13}

From March 8, 2020, DMA physicians prospectively questioned patients newly diagnosed with COVID-19 who were awaiting hospitalization or facility isolation regarding the presence of anosmia or ageusia; they also provided counseling on a daily basis for these symptoms until admission to hospitals or therapeutic living centers.

The data collected on anosmia or ageusia during the telephone severity scoring performed from March 8, 2020 to March 31, 2020, were analyzed retrospectively for the evaluation of the diagnostic significance of anosmia or ageusia in COVID-19. Additional telephone calls were made after admission to assess the duration of symptom persistence among those who reported that anosmia or ageusia persisted until hospitalization or facility isolation.

We analyzed the collected data using descriptive statistics and Kaplan-Meier analysis for the evaluation of factors associated with the recovery from anosmia or ageusia. Statistical analyses were performed using R statistics version 3.5.

Approximately 15% (15.3%, 488/3,191) patients had anosmia or ageusia in the early stage of COVID-19 (Fig. 1). Among patients with asymptomatic-to-mild disease severity (2,342 patients), 367 (15.7%) had anosmia or ageusia. The basic characteristics of the patients with or without anosmia or ageusia are summarized in Table 1. Anosmia or ageusia was significantly more common among females and younger individuals ($P = 0.01$ and $P < 0.001$, respectively) (Table 1).

![Fig. 1. Proportion of anosmia or ageusia in patients with coronavirus disease 2019 confirmed by polymerase chain reaction.](https://jkms.org/page1)
The duration of these two symptoms was ascertained based on the daily interviews conducted by DMA physicians during the waiting period for hospitalization or facility isolation and by follow-up telephone interviews with 232 (for anosmia) and 196 (for ageusia) patients. Recovery from anosmia is expressed using a survival curve (Fig. 2A). Kaplan-Meier graphs with log-rank tests were generated using data on recovery from anosmia based on demographic variables including age of > 50 years and sex. No significant differences were observed in log-rank tests.

The median time to recovery from anosmia was 7 days, and the recovery time pattern is depicted in Fig. 2B. The median time to recovery from ageusia was 7 days, and the recovery

---

**Table 1. Basic characteristics of patients with confirmed COVID-19 with or without anosmia or ageusia**

| Variables                                      | Absence of anosmia or ageusia (n = 2,703) | Presence of anosmia or ageusia (n = 488) | Total (n = 3,191) | P value |
|------------------------------------------------|------------------------------------------|------------------------------------------|-------------------|---------|
| Sex                                            |                                          |                                          |                   |         |
| Male                                           | 1,009 (37.3)                             | 152 (31.1)                               | 1,161 (36.4)      | 0.010   |
| Female                                         | 1,694 (62.7)                             | 336 (68.9)                               | 2,030 (63.6)      |         |
| Age at diagnosis, yr                           | 46.0 (25.0–59.0)                         | 36.5 (24.5–54.0)                         | 44.0 (25.0–58.0)  | < 0.001 |
| Duration of anosmia, day                       | -                                        | 7.0 (4.0–11.0)                           | 7.0 (4.0–11.0)    |         |
| Duration of ageusia, day                       | -                                        | 6.0 (3.0–10.0)                           | 6.0 (3.0–10.0)    |         |
| Severity of COVID-19                           |                                          |                                          |                   |         |
| Asymptomatic to mild                           | 1,975 (84.7)                             | 367 (79.6)                               | 2,342 (83.9)      |         |
| Moderate                                       | 271 (11.6)                               | 68 (14.8)                                | 339 (12.1)        |         |
| Severe                                         | 55 (2.4)                                 | 16 (3.5)                                 | 71 (2.5)          |         |
| Critical                                       | 31 (1.3)                                 | 10 (2.2)                                 | 41 (1.5)          | 0.046   |
| Daegu Severity Score for COVID-19 > 3          |                                          |                                          |                   | 0.292   |
| Yes                                            | 425 (15.7)                               | 67 (13.7)                                | 492 (15.4)        |         |
| No                                             | 2,278 (84.3)                             | 421 (86.3)                               | 2,699 (84.6)      |         |
| Age > 60 years                                 |                                          |                                          |                   | < 0.001 |
| Yes                                            | 589 (21.8)                               | 69 (14.1)                                | 658 (20.6)        |         |
| No                                             | 2,114 (78.2)                             | 419 (85.9)                               | 2,533 (79.4)      |         |
| Hypertension                                   |                                          |                                          |                   | 0.127   |
| Yes                                            | 274 (10.1)                               | 38 (7.8)                                 | 312 (9.8)         |         |
| No                                             | 2,429 (89.9)                             | 450 (92.2)                               | 2,879 (90.2)      |         |
| Diabetes mellitus                              |                                          |                                          |                   | 0.897   |
| Yes                                            | 140 (5.2)                                | 24 (4.9)                                 | 164 (5.1)         |         |
| No                                             | 2,563 (94.8)                             | 464 (95.1)                               | 3,027 (94.9)      |         |
| Cancer                                         |                                          |                                          |                   | 0.053   |
| Yes                                            | 29 (1.1)                                 | 11 (2.3)                                 | 40 (1.3)          |         |
| No                                             | 2,674 (98.9)                             | 477 (97.7)                               | 3,151 (98.7)      |         |
| End-stage renal failure                        |                                          |                                          |                   | 1.000   |
| Yes                                            | 1 (0.0)                                  | 0 (0.0)                                  | 1 (0.0)           |         |
| No                                             | 2,702 (100.0)                            | 488 (100.0)                              | 3,190 (100.0)     |         |
| Chronic lung diseases                          |                                          |                                          |                   | 1.000   |
| Yes                                            | 36 (1.3)                                 | 6 (1.2)                                  | 42 (1.3)          |         |
| No                                             | 2,667 (98.7)                             | 482 (98.8)                               | 3,149 (98.7)      |         |
| Congestive heart failure                       |                                          |                                          |                   | 0.742   |
| Yes                                            | 5 (0.2)                                  | 0 (0.0)                                  | 5 (0.2)           |         |
| No                                             | 2,698 (99.8)                             | 488 (99.8)                               | 3,186 (99.8)      |         |
| Cardiac diseases without congestive heart failure |                                    |                                          |                   | 0.311   |
| Yes                                            | 48 (1.8)                                 | 13 (2.7)                                 | 61 (1.9)          |         |
| No                                             | 2,655 (98.2)                             | 475 (97.3)                               | 3,130 (98.1)      |         |
| Use of immunosuppressants                      |                                          |                                          |                   | 0.255   |
| Yes                                            | 27 (1.0)                                 | 8 (1.6)                                  | 35 (1.1)          |         |
| No                                             | 2,676 (99.0)                             | 480 (98.4)                               | 3,156 (98.9)      |         |

Data are presented as number (%) or median (interquartile range).
COVID-19 = coronavirus disease 2019.
time pattern is shown in Fig. 2C. Most patients with anosmia or ageusia recovered within 3 weeks (Fig. 2B and C). Young age, particularly the age group of 20–39 years, showed a tendency to be associated with a longer persistence of anosmia (Fig. 2D). Recovery from ageusia was similar to that from anosmia (Supplementary Fig. 1). Recently, anosmia was reported in a small cross-sectional survey study of COVID-19.\textsuperscript{11} This article did not report follow-up information and included a relatively small number of patients (59 patients). Our data were derived from 3,191 patients, among whom 232 (anosmia) and 143 (ageusia) were followed up regarding the persistence of these symptoms.

Smell and taste disorders are related to a wide range of viral infections.\textsuperscript{2,3} Infection of the upper respiratory tract can cause acute-onset anosmia or ageusia because of viral damage to the olfactory epithelium.\textsuperscript{3} Moreover, viruses that can use the olfactory nerve as a route into the central nervous system include influenza A virus, herpesviruses, poliovirus, rabies virus, parainfluenza virus, adenoviruses, and Japanese encephalitis virus.\textsuperscript{2} In mouse models, SARS-CoV demonstrated transneuronal penetration through the olfactory bulb and its infection resulted in the rapid, transneuronal spread of the virus to connected areas of the brain.\textsuperscript{14}
In COVID-19, headache may not only be a constitutional symptom but also be a symptom induced by invasion of the central nervous system. Human angiotensin-converting enzyme 2 is a functional receptor for SARS-CoV-2.\textsuperscript{10,12}

Damage to the olfactory nerve during invasion and multiplication of SARS-CoV-2 may explain anosmia observed in the early stage of COVID-19. Therefore, anosmia or ageusia may be more frequently observed in the COVID-19 patients than other respiratory viral infections.

Ageusia may be a secondary result of olfactory dysfunction. However, the angiotensin-converting enzyme 2 receptor, which is the main host cell receptor of SARS-CoV-2 for binding and penetrating cells, is widely expressed on epithelial cells of the oral mucosa.\textsuperscript{15} Damage of mucosal epithelial cells of the oral cavity may explain ageusia observed in the early stage of COVID-19. This evidence may explain the pathogenetic mechanism underlying anosmia and ageusia in COVID-19.

High transmissibility of COVID-19 before and immediately after symptom onset was reported with a recent epidemic study.\textsuperscript{16} Early diagnosis is important for the control of COVID-19, recognition of early signs such as anosmia or ageusia might be very helpful for the diagnosis COVID-19 and isolation of the patients.

This telephone severity scoring system had a limitation regarding the accuracy of the assessment of patients. However, anosmia and ageusia are not ambiguous symptoms. Our report had a relatively large number of patients and focused on the time pattern on the recovery of these symptoms.

In conclusion, anosmia and ageusia seem to be part of important symptoms and clues for the diagnosis of COVID-19, particularly in the early stage of the disease. The acute anosmia or ageusia need to be recognized as important symptoms of the COVID-19 infection.

Among patients with asymptomatic-to-mild disease severity, the presence of anosmia or ageusia may be an important differential presentation for the suspicion and diagnosis of COVID-19. And these symptoms may recover within 3 weeks.

\textbf{ACKNOWLEDGMENTS}

The authors would like to thank all physicians of Daegu Medical Association who volunteered to interview and counsel patients with COVID-19 in Daegu, Korea.

\textbf{SUPPLEMENTARY MATERIAL}

\textbf{Supplementary Fig. 1}

Recovery from ageusia.

Click here to view

https://doi.org/10.3346/jkms.2020.35.e174
REFERENCES

1. Kim SW, Lee KS, Kim K, Lee JJ, Kim JY, Association DMDaegu Medical Association. A brief telephone severity scoring system and therapeutic living centers solved acute hospital-bed shortage during the COVID-19 outbreak in Daegu, Korea. J Korean Med Sci 2020;35(15):e152.

2. van Riel D, Verdijk R, Kuiken T. The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system. J Pathol 2015;235(2):277-87.

3. Hummel T, Landis BN, Hüttenbrink KB. Smell and taste disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg 2011;10:Doc04.

4. Yang X, Yu Y, Xu J, Shu H, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8(5):S2213-2600(20)30079-5.

5. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41(2):145-51.

6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507-13.

7. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708-20.

8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506.

9. Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean Cohort Study on COVID-19. J Korean Med Sci 2020;35(13):e142.

10. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. Forthcoming 2020.

11. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. Forthcoming 2020.

12. Eliezer M, Hautefort C, Hamel AL, Verillaud B, Herman P, Houdart E, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg. Forthcoming 2020.

13. Jang Y, Son HJ, Lee S, Lee EJ, Kim TH, Park SY. Olfactory and taste disorder: the first and only sign in a patient with SARS-CoV-2 pneumonia. Infect Control Hosp Epidemiol. Forthcoming 2020.

14. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol 2008;82(15):7264-75.

15. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020;12(1):8.

16. Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH, et al. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. Forthcoming 2020.